The dopamine transporter: A crucial component regulating dopamine transmission
Identifieur interne : 008268 ( Main/Merge ); précédent : 008267; suivant : 008269The dopamine transporter: A crucial component regulating dopamine transmission
Auteurs : Mohamed Jaber [États-Unis, France] ; Sara Jones [États-Unis] ; Bruno Giros [États-Unis] ; Caron [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-09.
Descripteurs français
- Wicri :
- topic : Toxicomanie.
English descriptors
- KwdEn :
- Amphetamines (pharmacology), Animals, Brain, Brain (metabolism), Carrier Proteins (genetics), Carrier Proteins (physiology), Central Nervous System Stimulants (pharmacology), Cocaine (pharmacology), Disease Models, Animal, Dopamine (metabolism), Dopamine Plasma Membrane Transport Proteins, Dopamine Uptake Inhibitors (pharmacology), Dopamine transmission, Dopamine transporter, Drug addiction, Gene Dosage, Gene knockout procedure, Genotype, Homeostasis (genetics), Homeostasis (physiology), Humans, Hyperkinesis (chemically induced), Hyperkinesis (genetics), Hyperkinesis (physiopathology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (physiology), Membrane Transport Proteins, Mice, Mice, Knockout, Mice, Transgenic, Nerve Tissue Proteins, Parkinson Disease (physiopathology), Parkinson's disease, Phenotype, Rats, Schizophrenia, Schizophrenia (drug therapy), Schizophrenia (physiopathology), Substance-Related Disorders (physiopathology).
- MESH :
- chemical , genetics : Carrier Proteins, Membrane Glycoproteins.
- chemical , metabolism : Dopamine.
- chemical , pharmacology : Amphetamines, Central Nervous System Stimulants, Cocaine, Dopamine Uptake Inhibitors.
- chemical , physiology : Carrier Proteins, Homeostasis, Membrane Glycoproteins.
- chemically induced : Hyperkinesis.
- drug therapy : Schizophrenia.
- genetics : Homeostasis, Hyperkinesis.
- metabolism : Brain.
- physiopathology : Hyperkinesis, Parkinson Disease, Schizophrenia, Substance-Related Disorders.
- Animals, Disease Models, Animal, Dopamine Plasma Membrane Transport Proteins, Gene Dosage, Genotype, Humans, Membrane Transport Proteins, Mice, Mice, Knockout, Mice, Transgenic, Nerve Tissue Proteins, Phenotype, Rats.
Abstract
The dopamine system is implicated in the control of locomotion, cognition, and endocrine function, The relative contribution of the various dopamine‐related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this “genetic defect.” leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter‐acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.
Url:
DOI: 10.1002/mds.870120502
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C94
- to stream Istex, to step Curation: 001C94
- to stream Istex, to step Checkpoint: 003863
- to stream PubMed, to step Corpus: 004615
- to stream PubMed, to step Curation: 004615
- to stream PubMed, to step Checkpoint: 004552
- to stream Ncbi, to step Merge: 004D68
- to stream Ncbi, to step Curation: 004D68
- to stream Ncbi, to step Checkpoint: 004D68
Links to Exploration step
ISTEX:4D41D4FA4980D7F0142DD24CB01586342180EF68Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The dopamine transporter: A crucial component regulating dopamine transmission</title><author><name sortKey="Jaber, Mohamed" sort="Jaber, Mohamed" uniqKey="Jaber M" first="Mohamed" last="Jaber">Mohamed Jaber</name></author><author><name sortKey="Jones, Sara" sort="Jones, Sara" uniqKey="Jones S" first="Sara" last="Jones">Sara Jones</name></author><author><name sortKey="Giros, Bruno" sort="Giros, Bruno" uniqKey="Giros B" first="Bruno" last="Giros">Bruno Giros</name></author><author><name sortKey="Caron" sort="Caron" uniqKey="Caron" last="Caron">Caron</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4D41D4FA4980D7F0142DD24CB01586342180EF68</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120502</idno><idno type="url">https://api.istex.fr/document/4D41D4FA4980D7F0142DD24CB01586342180EF68/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C94</idno><idno type="wicri:Area/Istex/Curation">001C94</idno><idno type="wicri:Area/Istex/Checkpoint">003863</idno><idno type="wicri:doubleKey">0885-3185:1997:Jaber M:the:dopamine:transporter</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9380041</idno><idno type="wicri:Area/PubMed/Corpus">004615</idno><idno type="wicri:Area/PubMed/Curation">004615</idno><idno type="wicri:Area/PubMed/Checkpoint">004552</idno><idno type="wicri:Area/Ncbi/Merge">004D68</idno><idno type="wicri:Area/Ncbi/Curation">004D68</idno><idno type="wicri:Area/Ncbi/Checkpoint">004D68</idno><idno type="wicri:doubleKey">0885-3185:1997:Jaber M:the:dopamine:transporter</idno><idno type="wicri:Area/Main/Merge">008268</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The dopamine transporter: A crucial component regulating dopamine transmission</title><author><name sortKey="Jaber, Mohamed" sort="Jaber, Mohamed" uniqKey="Jaber M" first="Mohamed" last="Jaber">Mohamed Jaber</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Current Address: CNRS UMR 5541, Université de Bordeaux II, Bordeaux Cedex; and B. Giros, INSERM U‐288, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Jones, Sara" sort="Jones, Sara" uniqKey="Jones S" first="Sara" last="Jones">Sara Jones</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Giros, Bruno" sort="Giros, Bruno" uniqKey="Giros B" first="Bruno" last="Giros">Bruno Giros</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Caron" sort="Caron" uniqKey="Caron" last="Caron">Caron</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-09">1997-09</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="629">629</biblScope><biblScope unit="page" to="633">633</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4D41D4FA4980D7F0142DD24CB01586342180EF68</idno><idno type="DOI">10.1002/mds.870120502</idno><idno type="ArticleID">MDS870120502</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amphetamines (pharmacology)</term><term>Animals</term><term>Brain</term><term>Brain (metabolism)</term><term>Carrier Proteins (genetics)</term><term>Carrier Proteins (physiology)</term><term>Central Nervous System Stimulants (pharmacology)</term><term>Cocaine (pharmacology)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Dopamine Uptake Inhibitors (pharmacology)</term><term>Dopamine transmission</term><term>Dopamine transporter</term><term>Drug addiction</term><term>Gene Dosage</term><term>Gene knockout procedure</term><term>Genotype</term><term>Homeostasis (genetics)</term><term>Homeostasis (physiology)</term><term>Humans</term><term>Hyperkinesis (chemically induced)</term><term>Hyperkinesis (genetics)</term><term>Hyperkinesis (physiopathology)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (physiology)</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Nerve Tissue Proteins</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson's disease</term><term>Phenotype</term><term>Rats</term><term>Schizophrenia</term><term>Schizophrenia (drug therapy)</term><term>Schizophrenia (physiopathology)</term><term>Substance-Related Disorders (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Carrier Proteins</term><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amphetamines</term><term>Central Nervous System Stimulants</term><term>Cocaine</term><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Carrier Proteins</term><term>Homeostasis</term><term>Membrane Glycoproteins</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Toxicomanie</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hyperkinesis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Homeostasis</term><term>Hyperkinesis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hyperkinesis</term><term>Parkinson Disease</term><term>Schizophrenia</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Gene Dosage</term><term>Genotype</term><term>Humans</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Nerve Tissue Proteins</term><term>Phenotype</term><term>Rats</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The dopamine system is implicated in the control of locomotion, cognition, and endocrine function, The relative contribution of the various dopamine‐related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this “genetic defect.” leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter‐acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.</div></front></TEI><double doi="10.1002/mds.870120502"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The dopamine transporter: A crucial component regulating dopamine transmission</title><author><name sortKey="Jaber, Mohamed" sort="Jaber, Mohamed" uniqKey="Jaber M" first="Mohamed" last="Jaber">Mohamed Jaber</name></author><author><name sortKey="Jones, Sara" sort="Jones, Sara" uniqKey="Jones S" first="Sara" last="Jones">Sara Jones</name></author><author><name sortKey="Giros, Bruno" sort="Giros, Bruno" uniqKey="Giros B" first="Bruno" last="Giros">Bruno Giros</name></author><author><name sortKey="Caron" sort="Caron" uniqKey="Caron" last="Caron">Caron</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4D41D4FA4980D7F0142DD24CB01586342180EF68</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120502</idno><idno type="url">https://api.istex.fr/document/4D41D4FA4980D7F0142DD24CB01586342180EF68/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C94</idno><idno type="wicri:Area/Istex/Curation">001C94</idno><idno type="wicri:Area/Istex/Checkpoint">003863</idno><idno type="wicri:doubleKey">0885-3185:1997:Jaber M:the:dopamine:transporter</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The dopamine transporter: A crucial component regulating dopamine transmission</title><author><name sortKey="Jaber, Mohamed" sort="Jaber, Mohamed" uniqKey="Jaber M" first="Mohamed" last="Jaber">Mohamed Jaber</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Current Address: CNRS UMR 5541, Université de Bordeaux II, Bordeaux Cedex; and B. Giros, INSERM U‐288, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Jones, Sara" sort="Jones, Sara" uniqKey="Jones S" first="Sara" last="Jones">Sara Jones</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Giros, Bruno" sort="Giros, Bruno" uniqKey="Giros B" first="Bruno" last="Giros">Bruno Giros</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Caron" sort="Caron" uniqKey="Caron" last="Caron">Caron</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-09">1997-09</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="629">629</biblScope><biblScope unit="page" to="633">633</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4D41D4FA4980D7F0142DD24CB01586342180EF68</idno><idno type="DOI">10.1002/mds.870120502</idno><idno type="ArticleID">MDS870120502</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brain</term><term>Dopamine transmission</term><term>Dopamine transporter</term><term>Drug addiction</term><term>Gene knockout procedure</term><term>Parkinson's disease</term><term>Schizophrenia</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Toxicomanie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The dopamine system is implicated in the control of locomotion, cognition, and endocrine function, The relative contribution of the various dopamine‐related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this “genetic defect.” leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter‐acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The dopamine transporter: a crucial component regulating dopamine transmission.</title><author><name sortKey="Jaber, M" sort="Jaber, M" uniqKey="Jaber M" first="M" last="Jaber">M. Jaber</name><affiliation wicri:level="1"><nlm:affiliation>Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710</wicri:regionArea><wicri:noRegion>North Carolina 27710</wicri:noRegion></affiliation></author><author><name sortKey="Jones, S" sort="Jones, S" uniqKey="Jones S" first="S" last="Jones">S. Jones</name></author><author><name sortKey="Giros, B" sort="Giros, B" uniqKey="Giros B" first="B" last="Giros">B. Giros</name></author><author><name sortKey="Caron, M G" sort="Caron, M G" uniqKey="Caron M" first="M G" last="Caron">M G Caron</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9380041</idno><idno type="pmid">9380041</idno><idno type="doi">10.1002/mds.870120502</idno><idno type="wicri:Area/PubMed/Corpus">004615</idno><idno type="wicri:Area/PubMed/Curation">004615</idno><idno type="wicri:Area/PubMed/Checkpoint">004552</idno><idno type="wicri:Area/Ncbi/Merge">004D68</idno><idno type="wicri:Area/Ncbi/Curation">004D68</idno><idno type="wicri:Area/Ncbi/Checkpoint">004D68</idno><idno type="wicri:doubleKey">0885-3185:1997:Jaber M:the:dopamine:transporter</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The dopamine transporter: a crucial component regulating dopamine transmission.</title><author><name sortKey="Jaber, M" sort="Jaber, M" uniqKey="Jaber M" first="M" last="Jaber">M. Jaber</name><affiliation wicri:level="1"><nlm:affiliation>Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710</wicri:regionArea><wicri:noRegion>North Carolina 27710</wicri:noRegion></affiliation></author><author><name sortKey="Jones, S" sort="Jones, S" uniqKey="Jones S" first="S" last="Jones">S. Jones</name></author><author><name sortKey="Giros, B" sort="Giros, B" uniqKey="Giros B" first="B" last="Giros">B. Giros</name></author><author><name sortKey="Caron, M G" sort="Caron, M G" uniqKey="Caron M" first="M G" last="Caron">M G Caron</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amphetamines (pharmacology)</term><term>Animals</term><term>Brain (metabolism)</term><term>Carrier Proteins (genetics)</term><term>Carrier Proteins (physiology)</term><term>Central Nervous System Stimulants (pharmacology)</term><term>Cocaine (pharmacology)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Dopamine Uptake Inhibitors (pharmacology)</term><term>Gene Dosage</term><term>Genotype</term><term>Homeostasis (genetics)</term><term>Homeostasis (physiology)</term><term>Humans</term><term>Hyperkinesis (chemically induced)</term><term>Hyperkinesis (genetics)</term><term>Hyperkinesis (physiopathology)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (physiology)</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Nerve Tissue Proteins</term><term>Parkinson Disease (physiopathology)</term><term>Phenotype</term><term>Rats</term><term>Schizophrenia (drug therapy)</term><term>Schizophrenia (physiopathology)</term><term>Substance-Related Disorders (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Carrier Proteins</term><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amphetamines</term><term>Central Nervous System Stimulants</term><term>Cocaine</term><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hyperkinesis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Homeostasis</term><term>Hyperkinesis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Carrier Proteins</term><term>Homeostasis</term><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hyperkinesis</term><term>Parkinson Disease</term><term>Schizophrenia</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Gene Dosage</term><term>Genotype</term><term>Humans</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Nerve Tissue Proteins</term><term>Phenotype</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The dopamine system is implicated in the control of locomotion, cognition, and endocrine function. The relative contribution of the various dopamine-related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this "genetic defect," leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter-acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 008268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:4D41D4FA4980D7F0142DD24CB01586342180EF68
|texte= The dopamine transporter: A crucial component regulating dopamine transmission
}}
| This area was generated with Dilib version V0.6.23. |  |